Home Newsfeeds Morgan Stanley Downgrades Core Laboratories to Underweight, Announces $20 Price Target

Morgan Stanley Downgrades Core Laboratories to Underweight, Announces $20 Price Target

Morgan Stanley analyst Connor Lynagh downgrades Core Laboratories (NYSE:CLB) from Equal-Weight to Underweight and announces $20 price target.

byBenzinga Newsdesk

September 26, 2022

1 minute read

Morgan Stanley analyst Connor Lynagh downgrades Core Laboratories (NYSE:CLB) from Equal-Weight to Underweight and announces $20 price target.

News

Why Meta Materials (MMAT) Shares Are Falling

By Henry Khederian

May 6, 9:50 AM

Meta Materials shares are trading lower by 24% during Monday's session. The company late Friday announced a significant reduction in its workforce.

MMAT

AbbVie Showcases Breadth And Depth Of Research In Crohn’s Disease And Ulcerative Colitis At UEG Week 2023

By Benzinga Newsdesk

October 10, 8:49 AM

– Late-breaking data from a head-to-head study evaluating SKYRIZI® (risankizumab) versus STELARA® (ustekinumab) in moderate to severe Crohn's disease will be presented– Analyses on

ABBV

Telsey Advisory Group Reiterates Outperform on Westrock Coffee, Maintains $15 Price Target

By Benzinga Newsdesk

March 15, 5:15 AM

Telsey Advisory Group analyst Sarang Vora reiterates Westrock Coffee (NASDAQ:WEST) with a Outperform and maintains $15 price target.

WEST

News

Assertio Announces Partnership With The Lennox-Gastaut Syndrome Foundation

By Benzinga Newsdesk

January 17, 10:02 AM

SYMPAZAN® (clobazam) oral film from Assertio is used for the adjunctive treatment of seizures associated with LGS in patients two years of age and older Oral film delivery from SYMPAZAN® delivers

ASRT

Morgan Stanley Downgrades Core Laboratories to Underweight, Announces $20 Price Target

Related Posts

Why Meta Materials (MMAT) Shares Are Falling

AbbVie Showcases Breadth And Depth Of Research In Crohn’s Disease And Ulcerative Colitis At UEG Week 2023

Telsey Advisory Group Reiterates Outperform on Westrock Coffee, Maintains $15 Price Target

Assertio Announces Partnership With The Lennox-Gastaut Syndrome Foundation